Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Tunisie Medicale [La]. 2013; 91 (7): 435-439
in English | IMEMR | ID: emr-139654

ABSTRACT

The ectopic pregnancy [EP] is a public health problem and its frequency has doubled in most industrialized countries in 20 years. To evaluate the effectiveness of medical treatment of ectopic pregnancy with methotrexate [MTX] intramuscularly [IM]. prospective study supported between October 2006 and December 2010. The selected patients received methotrexate IM [1 mg per kg]. The monitoring was based on: the kinetics of plasma HCG, clinical examination and ultrasound. A second injection was performed if hCG on day 4 was increased by more than 25% or J7> the initial rate. Healing corresponded to obtain a zero rate of HCG in a stable manner. We used the first-line medical treatment in 122 patients. The average age of patients was 31.94 years. A haematosalpinx was found in 87.70% of cases. The initial rate of HCG plasma varied between 40 lU/ml and 4088 IU / ml, with an average of 805.88 m IU / ml. The primary success rate obtained after a single injection of intramuscular MTX was 67%. The high success rate obtained after two injections of MTX was 27%. The overall success rate after 1 or 2 injections of MTX was 82%. 17 patients underwent surgical treatment after a first injection of methotrexate. 5 patients underwent surgery after receiving two doses of methotrexate. The period of normalization of plasma levels of h CG was 24 days on average, with extremes ranging from 4 to 43 days for 67 patients cured after a single injection of MTX. This period was 33 days on average, with extremes ranging from 8 to 62 days for patients healed after two injections of MTX. Medical treatment applied to 38% of ectopic pregnancies diagnosed in our department is effective in 82% of cases if the inclusion criteria are strictly adhered to. Successful treatment is limited by patient compliance and demanding nature of monitoring


Subject(s)
Humans , Female , Methotrexate , Abortifacient Agents, Nonsteroidal , Treatment Outcome , Abortifacient Agents, Nonsteroidal/adverse effects , Injections, Intramuscular , Pelvic Pain/chemically induced , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL